ID   HBL
AC   CVCL_J075
DR   cancercelllines; CVCL_J075
DR   ChEMBL-Cells; CHEMBL3307524
DR   ChEMBL-Targets; CHEMBL614070
DR   Cosmic; 2051678
DR   PubChem_Cell_line; CVCL_J075
DR   Wikidata; Q54881423
RX   PubMed=2174414;
RX   PubMed=23489693;
RX   PubMed=25623468;
RX   PubMed=27540956;
WW   http://www.gentaur.com/melanoma_hbl_lnd1.htm
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Unspecified (PubMed=23489693).
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 05-10-23; Version: 14
//
RX   PubMed=2174414; DOI=10.1002/ijc.2910460629;
RA   Deschodt-Lanckman M.M., Vanneste Y., Loir B., Michel A., Libert A.,
RA   Ghanem G., Lejeune F.;
RT   "Degradation of alpha-melanocyte stimulating hormone (alpha-MSH) by
RT   CALLA/endopeptidase 24.11 expressed by human melanoma cells in
RT   culture.";
RL   Int. J. Cancer 46:1124-1130(1990).
//
RX   PubMed=23489693;
RA   Zanna P., Maida I., Grieco C., Guida S., Turpin Sevilla M.C.,
RA   De Summa S., Tommasi S., Vena G.A., Filotico R., Guida G.;
RT   "Three novel human sporadic melanoma cell lines: signaling pathways
RT   controlled by MC1R, BRAF and beta-catenins.";
RL   J. Biol. Regul. Homeost. Agents 27:131-141(2013).
//
RX   PubMed=25623468; DOI=10.1186/s12967-015-0385-4;
RA   Porcelli L., Guida G., Quatrale A.E., Cocco T., Sidella L., Maida I.,
RA   Iacobazzi R.M., Ferretta A., Stolfa D.A., Strippoli S., Guida S.,
RA   Tommasi S., Guida M., Azzariti A.;
RT   "Aurora kinase B inhibition reduces the proliferation of metastatic
RT   melanoma cells and enhances the response to chemotherapy.";
RL   J. Transl. Med. 13:26.1-26.13(2015).
//
RX   PubMed=27540956; DOI=10.1111/pcmr.12516;
RA   Guida M., Strippoli S., Ferretta A., Bartolomeo N., Porcelli L.,
RA   Maida I., Azzariti A., Tommasi S., Grieco C., Guida S., Albano A.,
RA   Lorusso V., Guida G.;
RT   "Detrimental effects of melanocortin-1 receptor (MC1R) variants on the
RT   clinical outcomes of BRAF V600 metastatic melanoma patients treated
RT   with BRAF inhibitors.";
RL   Pigment Cell Melanoma Res. 29:679-687(2016).
//